Benefits of implantable defibrillators are overestimated by sudden death rates and better represented by the total arrhythmic death rate  by Kim, Soo G. et al.
CARDIAC PACING 
Benefits of Implantable Defibrillators Are Overestimated by 
Sudden Death Rates and Better Represented by the Total Arrhytbmic 
Death Rate 
SO0 G. KIM, MD, FACC, JOHN D. FISHER. MD. FHCC. SEYMOUR FURMAN, MD, FACC, 
JAY GROSS, MD, PHILIP ZILO. MD. JAMES A. ROTH. MD. KEVIN 1. FERRICK. MD. FACC. 
RICHARD BRODMAN, MD, FACC 
Bronx, New York 
Benefits al the implantable d+tibrillator on rurrirat were studied 
in 56 cattseatlive patients koncomitattt cnronsry bypass or ar- 
rhythmin surgery in 15) duringart 8yerrperiod b&rem 198.2 and 
1990. During P iollow.up perlad of 29 * 25 mootbs. six patients 
had P s,tdden death and right pa”entr bad a nonmddeo cardiac 
death. Nmtsttddrn cardiac deaths included three rtttxicnl deaths 
(death within 38 days *rr the sttrgery; two in psdents without 
and ate in P wtierd with ccmcatttitattt cardiac wwry~, one 
nrrhy,bmia.rel&d ttomuddett death (death witbin 24 h anrr tttt 
arrhythmic event despite btitlal termination of the arrhythmia by 
91%. 91% and 87% for sudden dab and wrt#caJ nwtatity and 
89%. 89% and SsTb lor total arrbytbmic d&t lsuddeta death 
sur@l mortality and arrltyiltmia&ated dew. 
Thus, in patients treated tb an impllotalde defibrillator, 1) 
the r&e of suddrro death b low (8% 11 3 years,; 2, 50% of 
nonsudden cardiac deaths are csuspUr related to arrh@ttia 
~surgicrd mortality (K arrbytlmda~&#ed wmudden doaL): 3) 
the total arrhjthttdc death rate is stdtstWia8y hi#tcr than the 
sudden death rate; attd 4) bate,% of an impkwttable detibrillator 
are avwpscimated by reported sttdden death attd tatsudden 
cardiac death rata. The batefits may bc better eprecoted by the 
total arrhythmic death pnd nonarrhytimdc cardiac death rata. 
,, An Cal; C&i01 1991;17:1587-92) 
Implantable automatic defibrillators have been used widely 
for the management of patients with maliqnant ventricular 
arrhythmias and their beneficial effects in preventing sudden 
cardiac death have been reported by many investtgator? 
(t-8). However. the incidence of aonsudden cardiac death 
remains substantial. Nonsudden cardiac deaths include SW 
&al mortality after defibrillator implantation and nonar- 
rhythmic death. In addition. ‘*not so sudden” arrhythmic 
deaths as described by Guamieri et al. 181 are classified as 
nonsudden death. Because nonwdden cardiac deaths in- 
clude deaths related to the arrhythmia (such as urgical 
mortality and “not so sudden” arrhythmtc deaths). sudden 
death rates may ttot represent he true benefit and risk of the 
defibrillator therapy. This study was done to address this 
issue. 
Methods 
Study patients. Fihy-six consecutive patients who under- 
went imp&&m of an automatic defibrillator for malignant 
ventricular arrhvthmias at Mont&ore Hospital Medical Cen- 
terduringthe p&d between May I. 1982atd December31, 
1989 wcrc studied. Informed consent was obtained from ail 
patients. The protocol was approved by the lnslitutianal 
Research Review Committee in April 1982. Forty-two pa- 
tients underwent implantation of a defibrillator withour con- 
comitant surgery. Eight patients had concomitant coronary 
bypass surgery: one of these patients also bad mitral valve 
replacement. Six patients underwent concomitant surgery 
for arrhythmias, including endacardial resection (four pa- 
tients) (9). cyrosurgery (one patient) (IO) and septal my0 
mectomy (one pstient) (I I). 
Thirty-seven patients had sustained ventricular tachycar- 
dins and I9 patients bad ventricular fibrillation. Sustained 
ventricular tachycardia was defined as ventricular tachycar- 
db Wing >3lJ s or requiring immediate temtination by 
electric cardioversion because of bemodynamic collapse. 
There were 42 men and 14 watten with a mean age of 59 + 
IO years. Corottary anery disease was present in 43 pa:ionts. 
dilated cardiomyopathy in 7, valvular heal disease tn 3. 
amyloid heart disease in 2 and hypertrophic ardiomyopathy 
in I patient. The mean left ventriculw ejection fraction was 
33 2 15%. 
?\rrhythmia drug therapy. All 56 patients underwent se- 
rial drug tehting hy programmed stimulation and ambulatory 
eleclrocardiographic IECG) momtaring (IZ-I61 before the 
implanlalion. An antiarrhythmic regimen was selected on 
the basis of the resuh?, of serial drug rating. The defibrillator 
therapy was not gwen to pstients whose ventricular tachy- 
cardia induced by programmed stimulation was slower and 
better tolerated during drug therapy and whrlse spontaneous 
arrhythmias were reduced during Holler ECG monitoring 
il2-161. In five patients. no anliarrhythmic agents were 
given bccaux no lhcrapy was consldercd beneficial by 
invasive or nonirwasive evaluation of antiarrhythmic ef- 
ficacy (I?-161. In six patients who had concomitant surgery 
for arrhythmias. aniiarrhythmic drug therapy was chosen on 
the bais of postoperative drug testing. 
IJo poritvr hod ,rwrwnl .w.vnincd wnrricrrlor rrrI~ww- 
&I drrrinl: rk~~po.\fi~~,pcnrril~~~ period while rn’uiGp /he s~mc 
onriorrhyrlw~ir repimrn. a different antisrrhythmic regimen 
w.5 prescribed as guided by programmed sfimuladon and 24 
hour ambulatory ECC monitoring. If a patient had freqoenl 
and Fast nonsustained ventricular tachycardias postoperh- 
lively while receiving the regimen that had controlled spon- 
taneous nonsuslained ventricular txhycardia before sur- 
gery. the patient also was given a di&nt anliarrbythmic 
regimen lo prevent triggering of the defibrillator by such 
arrhythmias (6). The de&on to change amiarrhythmic 
rcgimcns in pattent with frequent nonsustained ventricular 
tachycardia was based not on quantitative assessments by 
ambulatory ECG monitoring but on findings on the telemetry 
monilor and clinical JUd$ment of the investigaron. 
Implantation of an automatic defibrillator. The electrode- 
lead system used included a spring-patch configorarioo (6) in 
8 patientk a patch-patch configuration 161 in 46 and a 
transvenoos lead-subcutzaneous patch configuration (Endo- 
tak system) (171 in 2. A median sterootomy (6) was used in 42 
patients. a lateral thoracotomy (6) in 9. B subcostel approach 
(6) in 3 and a transvenous and subcutaneous approach (for 
Endolak) (17) in 2. 
Follow-op. All patients were followed UP by the Arrhvth- 
mia Service of our institution ot intervals of I fo 2 r&hs. 
The end point of follow-up study was one of the followinc: 
sudden cardiac death. in-hospital dea!h. arrhythmia-related 
nonrudden death. nonarrhythmic cardiac death. noncardiac 
death or arrhythmia-free survival as of February I. 1990. 
Sudden death was defined as inslanlaneour or unwitnessed 
death. usually during sleep. Sure’ .I mortalny WRS defined 
BS death in the host&l within 30 days after &plantation of 
the defibrillator (7). Arrhythmia-related nonsudden death 
was defined as death within 24 h after having multiple 
sustained ventricular tachycardia terminated by the defibril- 
lator. Total arrhythmia death was defined as any sudden 
death. surgical death or arrhylhmia-related nonsudden 
death. The following events were also noted during the 
follow-up period: an appropriate discharge from the detibril- 
later after the patient had left the hospital and explant&n 
of B defibrillator. An appropriate discharge was defined as a 
discharge from the defibrillator preceded by dizziness. syn- 
cope or ventricular tachycardia documented on the ECG. 
Statistical methods. Mean values ? SD were used as the 
index of dispersion of observed values. One-way analysis of 
variance &NOVA). the Kruskal-Wattis test or chi&uare 
test was used to compare appropriate variables between 
groups. The Kaplan-Meier method was used to generate 
acluxial survival curves for each group. Analyses were 
made according to the intention to treat. A two-tailed p value 
< 0.05 was considered significant. 
Results 
Postoperative eourw. One patient who had been in stable 
condition without heart failure before defibrillator implanta- 
tion developed progressive pump failure without ventricular 
arrhythmias and died 5 days after implantation. He had 
coronary disease and o left ventricular ejection fraction of 
24%. His heart failure had been well compensated before the 
implantation surgery. One patient with coronary disease and 
an ejection fraction of 29% who had been in stable condition 
without recurrence of ventricular tachycardia for >30 days 
before defibrillator implantation developed multiple stts- 
mined venlricular txh&dia within 24 h’after imPiantedion 
and eventually died because of:efractory ventricular tachy- 
cardia 22 days after implantation. These two patients did not 
have concomitant coronary bypass or arrhythmia surgery. 
One patient with dilated cardiomyopathy and recurrent. well 
tolerated ventricular tachycardia. who underwent implanta- 
tion of a defibrillator and cryosurgery for ventricular lachy 
cardia originating from the epicardium. developed multiple 
episodes of fater. poorly tolerated ventricular tachycardia 
and ventricular fibrillation 3 days oostooeratively and died 
on that day. Preoperatively. the recu&nce of ;entricular 
tachycardia in this patient had been infrequent (a few times 
per year) and he had not had clinical congestive heart failure 
(New York Heart Association functional class 1) despite a 
low ejection fraction of 19%. Therefore, 3 of the 56 patients 
died within 30 days after implantation surgery. with a 
surgical mort&ty rate of 5.4% (4.9% for defibrillator implan- 
tation alone and 6.6% for defibrillator implantation and 
concomitant surgery) 171. 
OJ lhr rwnuining 53 pohw~. 7 were discharged from the 
hospital wilhout antiarrhythmic drug therapy (defibrillator 
implantation alone in 5 patients and concomitant arrhythmia 
surgery in 21 and 46 patients were discharged with antiar. 
rhythmic drug therapy (defibrillator implantation without 
other surgery in 35 patients and defibrillator implantation 
with coronary bypass surgery in 8 and with arrhythmia 
surgery in 31. 
Longterm followup. During the iollow~up period of 29.4 t 
25.1 months, there were three early surgical deaths (sudden 
death due to refractory ventricular tachycardia and fibrilla- 
tion on day 3. pump failure on day 5 and arrhythmia- 
related nonsudden death on day 22). six sudden deaths at 5. 
5. 29. 37. 37 and 51 months. respectively. one arrhythmia- 
related nonsudden death at 3 months. four nonarrhythmic 
cardiac deaths at 5. 16. 27 and 38 months and four noncar- 
disc deaths at 5. Ii. I3 and 42 months. In eight patients. the 
defibrillator was explanted for various reasons 25.4 2 22.1 
months after the initial implantation. Follow-up evaluation 
WIE continued in these eight patients (the intention to treat 
analysis). From the results. actuarial survival raw were 
generated and are summarized in Table I. The details of 
sudden deaths and tolal cardiac deaths during the initial 36 
months of follow-up are shown in Figure I. In Figure 2. the 
fame results are shown with a ditTerent scale on the vertical 
axis (survival rates) together with survival curves of sudden 
death, surgical mortality and the total anhythmic death 
(sudden death, surgical mortality and arrhythmia-related 
nonsudden death). 
Of eight padents whose dejbrillaror MS erplantrd. one 
patient died suddenly 25 months after explant&n. If fol- 
low-up study had been terminated at the time of sxplantation 
of the defibrillator in these eight patients, the actuarial 
survival rate by the Kaplan-Meier method would have been 
94%. 94%. 89%. 77% and 11% at I. 2. 3.4 and 5 years. for 
sudden death and 87%. 84%. 76%. 61% and 61% for lotal 
cxdiac death. reqxctivcly. The sunival rites are nor sig- 
nificantly different from those obtained by the intention IO 
treat analysis. 
The results of this study suggest hat during the long-term 
follow-up period. the rate of sudden death decreased signif- 
icantly compared with that in patients treated by other 
therapy 1131. However. the in-hospital mortality rate after 
the implantation of the defibrillator is not insignificant. The 
tulal &rhythmic death rate. including sudden death. surgical 
mortality and arrhythmia-r&led nonwdden death. re- 
muted s~gmficant. Many nonsudden deaths were causally 
related to arrhythmia (surgical marlality or arrbythmia- 
related nonsudden death). 
Iwhospital mortality. The short-term restdts of our study 
are similar to those in previous reports (5.7.18). In a study of 
lb3 patients treated with a defibrillator. Veltri et al. (5) 
reported that 8 padents (5%) died before discharge from the 
hospilal aRer implantation of a defibrillator compared with 3 
of jb patients (5.4%) in our study. From data compiled by a 
manufacturer of defibrillaton. Winkle and Thomas (7) re- 
ported that 40 (4.2%) of 949 palienls died within I month 
after the implantation lsurgical mortality). Nine of the 40 
pattents had a sudden death; 31 of the 40 patients did not 
have concomitant surgery and 9 had concomitant surgery. 
Therefore. in their study (7). 31 (4.6%) of 669 patients 
without concomitant surgery and 9 (3.2%) of 280 patients 
with concomitant surgery died within 30 days of defibrillator 
implantation. 
Other investigaton”~9.20~ have reported lower surgical 
mortality raw One group ! 19) reported a surgical monalily 
rate of 1.5% in a study of270 patients. The excellent ~stdt. 
which may be related to patient selection and surgical 
technique. may not be representative of results of many 
other university or commutdty hospitals where the implan- 
tation is now performed (5-8.18.21). With further develop- 
ment of technology. surgical risks will decrease. However, 
at presem. the surgical mortality rate ofimplantation in most 
hospitals appears to be significant. ranging between 4% and 
5%. 
Long-term follow-up. Different long-term outcomes of 
patients treated with a defibrillator have been reported 
(S-7.19-221. Yeltri et al. (5) reported that the mortality rate 
Srom ventricular tachyrerdia or ventricular fibrillation was 
2.8% and 7.7% at I and 2 years. respectively, compared with 
a sudden death rate of 4% and 4% respectively. during the 
same periods in our study. It appears that our results are not 
significantly different from their results when sudden death 
raterare considered. Veltri et al. (5). however. did not repon 
the total arhythmic death rate including surgical mortality 
and arrhythmia-related nonsudden death. The reason for 
including the surgical mortality when reporting the long-term 
outcome of patients treated with a defibrillator is obvious. 
Other investigators (7) also included the surgical mortality in 
reporting long-term outcome. 
Two patients in our study died within 24 h after multiple 
successful terminations of ventricular tachycardia by the 
defibrillator. Although such death does not meet the crite- 
rion for sudden cardiac death. il is obviously related to or 
caused by multiple episodes of malignant arrhythmias. The 
defibrillator terminated multiple episodes of malignant ar- 
rhythm& but did not prevent the patients from dying a few 
hours later in the hospital. For this reason, arrhythmia- 
related nonsudden death (a death within 24 h after successful 
termination of tachyarrhythmia by the defibrillator in thin 
study) should also be reponed as an arrhythmic death. 
The results compiled by a manufacturer of defibtillators 
and reported by Winkle and Thomas (7) appear to be 
somewhat better than the results of this study and those of 
Veltri et al. (5). However, as the authors of the report 
indicate, the data may have “underestimated the actual 
occ”rreoces of reported events*’ because of the data collec- 
tion method employed. In addition, patients who received 
the original automatic implantable defibrillator (AID) were 
not included in Ihe analysis and sudden death was not 
defined clearly in the report. The mean duration of follow-up 
was only I6 months in their study compaxd with 29 months 
in our study. 
The wttue of nonsudden de&. The ditTerence between 
total cardiac death and sudden cardiac death was reported as 
nonsudden death in most previous studies. Readers of such 
studies may get an impression that the nonsudden deaths 
(shown as the difference between sudden death and the total 
cardiac death in Fig. I) are nonarrhythmic deaths due to 
progressive heart disease or new myocardial infarction. 
However, surgical mortality and arrhythmia-related nonsud- 
den death are included in nonsudden cardiac death. Al- 
though this method of repotting may not he incorrect. it does 
not reflect the true death rate from arrhylhmia and overes- 
timates the efficacy of defibrillator therapy in pwentiog 
deaths from malignant arrhythmias. 
To ertimarr rhe rmd ! *ne~?t of defibrillator therapy in 
prevenring deuth front arrhyhmias, ok must consid& the 
rate of sudden death, surgical mortality and arrhythmia- 
related nonsudden death (the total arrhythmic mortality). 
When the total arrhythmic mortality is considered. the 
eficacy of the defibrillators becomes less dramatic (Fig. 2). 
True nonarrhythmic nonsudden death is represented by the 
d#erence between total cardiac death and total arrhythmic 
death (Fig. 2). One should also consider that some deaths, 
spy. may be considered noncardiac. a; in this study, P they 
occur >30 days after the implantation and thus arc not 
included in surgical mortalit;. This could underestimate 
death rates related to the arrhythmia and overestimate the 
benefit of defibrillator therapy. 
It has been suggested (23) that pattents who have never 
received an appropriate shock should be excluded from rhe 
survival analysis because they have not benefited from the 
defibrillator. In this study. however. ad parients were in- 
cluded in the analysis. 
Limitations of the study. The relatively small number of 
patients in this study may be a limitation. One may argue 
that the results. of our study may be an aberration because a 
large study (7) of 949 patients reported somewhat better 
results. However. that study (7) based on the data compiled 
by JJ manufacturer may have involved nonconsecutive pa- 
tients and incomplete data because “some implanting ten- 
ters failed to collect and/or provide” data. In fact. another 
large study by a single center (5) reported long-term out- 
comes similar to those in our study. Although the number of 
patient; may be smaller in our study. the duration of 
follow-up assessment is longer than in other studies. The 
mean follow-up period in the study by Winkle and Thomas 
(7) was Ih months compared with 29 months in our study. In 
our study, 20 patients were followed up for 7 years and were 
alive or reached one of the follow-uo end oomts. In fact. 
results from a multicenter registry of’implantable defibrilla- 
tars (the Bilitch Reoart 1221 camsiled bv IO maior imolantine 
cent&s) are sin& IO our results. In addition.*the r&tively 
small number of patients in our study does not undermine 
the desirability of using the method of reporting long-term 
outcomes employed in this study rather than methods used 
in other studies. 
Our study patients may be diffcxnr from those 61 other 
studies. Because of limited device availability as a result of 
production problems (7) during the early period of the study. 
patients who received defthrillatortherdpy during that period 
may have had more refractory arrhythmias compared with 
patients who received the therapy more recently. In addi- 
iion. because of our patient sele&n criteria using waive 
and noninvasive methods (see Methods). our patients may 
have had more refractory arrhythmias than patients in other 
studies. When a defibrillator is used in patients with less 
refractory arrhythmias. the overall outcome may be better 
than that reported in this study. 
Clinical implications. The results of this study do not 
negate the value of the automatic implantable defibrillator in 
the management of patients with malignant arrhythmias. 
However.~this study addresses problems assc&ed with 
reporting benefits and risks of defibrillator therapy. Although 
the rate of sudden death could he decreased significantly 
with an automatic defibrillator, the surgical mortality rate is 
not insignificant and the total arrhythmic death and total 
cardiac death rate remain relatively high. The common 
impression that all nonsudden deaths in these patients with 
termmal hear! dwase are due to progressive hcan disease I( 
mcorrect. Many nonsudden cardiac deaths are causally 
related to ventricular arrhythmia. either caused by the 
therapy Isurgcal mortality) or not prevenred by the therapy 
tarrhythmtc nonsudden cardiac death). The benefit of de- 
fibnllator therapy is overestimated when one considers only 
the sudden death rate without considenng the total arrhyth- 
mic death trudden death. surgical mortality and arrhythmia 
related nonwdden death) or total cardiac death rate. 
Some mvwigators (241 have suggested that all pattents 
with maligant ventricular tachyarrhythmia should be 
rreated with an implanrable defibnltator even when an effec- 
tive regimen by programmed srlmutation criteria could be 
identdied. Their argument may be based on the reported 
sudden death rates in patients treated with an implantable 
defibrillator. which are often lower than those m patients 
treated with antiarrhytbmic drugs That prevent the induction 
of ventricular tachycardia by programmed stimulation. Such 
an argument. however. is not valid because the sudden death 
rate overestimates the benefits of implanmble defibrilbzors 
in preventing arrhythmic death. The total arrhythmic death 
rate should be used to compare defibrillator therapy with 
other therapies. such as drug therapy guided by invasive or 
noninvasive methods, amiodamne therapy and arrhythmia 
surgery. Sudden death mtes should not be used to compare 
implantable defitrillator therapy with other therapies. 
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